Hnrnpa2B1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1), encoded by the HNRNPA2B1 gene, is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family of proteins that play critical roles in post-transcriptional RNA processing within eukaryotic cells. This protein has garnered significant attention in recent years due to its involvement in the pathogenesis of several neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). HnRNP A2/B1 is a multifunctional protein implicated in alternative splicing, mRNA transport, stress granule assembly, and telomere maintenance, making it essential for normal neuronal function and viability.
The protein is expressed predominantly in the nucleus of eukaryotic cells but can shuttle between the nucleus and cytoplasm, allowing it to participate in diverse cellular processes. Its ability to bind RNA through specialized domains enables it to regulate gene expression at multiple levels, from pre-mRNA processing to cytoplasmic mRNA localization and translation. The dysregulation or mutation of hnRNP A2/B1 has been directly linked to neurodegeneration, highlighting its importance in maintaining neuronal health.
The HNRNPA2B1 gene is located on chromosome 7p15.2 in humans and encodes the hnRNP A2/B1 protein through alternative splicing of its primary transcript. The gene produces multiple isoforms through differential splicing, with the two major isoforms being hnRNP A2 and hnRNP B1, which differ by the inclusion of a 12-amino acid insert in the B1 isoform [1]. The gene is highly conserved across mammalian species, reflecting its fundamental cellular functions.
Expression of HNRNPA2B1 is ubiquitous in human tissues, with particularly high levels observed in the brain, particularly in neurons of the cerebral cortex, hippocampus, and spinal cord. The gene promoter contains multiple regulatory elements that respond to cellular stress, growth factors, and developmental cues, allowing for tight spatial and temporal regulation of its expression [2]. Aberrant expression or alternative splicing of HNRNPA2B1 has been reported in various pathological conditions, including neurodegenerative diseases and multiple cancers.
HnRNP A2/B1 is a 353-amino acid protein with a molecular weight of approximately 36 kDa, characterized by several distinct structural domains that mediate its diverse functions:
The N-terminal region of hnRNP A2/B1 contains a glycine-rich low-complexity (LC) domain spanning approximately residues 1-175. This domain is rich in glycine, phenylalanine, and tyrosine residues, and is inherently disordered in solution, adopting a more ordered conformation upon interaction with other proteins or RNA [3]. The low-complexity domain is particularly notable because it harbors several disease-linked mutations that cause protein aggregation in neurodegenerative conditions.
The central region of hnRNP A2/B1 contains two highly conserved RNA recognition motifs (RRMs), also known as RNA-binding domains (RBDs). The first RRM (RRM1, residues 106-178) and the second RRM (RRM2, residues 191-258) each adopt the canonical β-α-β-β-α-β fold typical of RRM family proteins [4]. These domains specifically bind to RNA sequences containing the motif UAGGG, although the protein can recognize a broader range of RNA structures through cooperative binding. The RRMs are connected by a flexible linker that allows for conformational changes upon RNA binding.
The C-terminal region (residues 259-353) contains additional glycine-rich sequences and serves as a protein-protein interaction platform. This region mediates homotypic and heterotypic interactions with other hnRNP proteins, including hnRNP A1, hnRNP A3, and various members of the hnRNP C family [5]. The C-terminal region also contains nuclear localization signals (NLS) and nuclear export signals (NES), facilitating the shuttling of hnRNP A2/B1 between nuclear and cytoplasmic compartments.
Several crystal structures of hnRNP A2/B1 domains have been solved, providing atomic-level insights into the protein's RNA-binding mechanism. The PDB IDs 1H4D, 2D2V, and 5A3P represent structures of the RRM domains bound to RNA oligonucleotides [6]. These structures reveal the molecular basis for sequence-specific RNA recognition and demonstrate how the RRM domains use conserved aromatic residues to stack with RNA bases.
HnRNP A2/B1 is expressed in virtually all human tissues, with the highest levels found in tissues with high transcriptional and metabolic activity. In the central nervous system, hnRNP A2/B1 is expressed abundantly in neurons throughout the brain and spinal cord. Immunohistochemical studies have shown particularly high expression in:
The protein localizes predominantly to the nucleus in resting cells but can accumulate in cytoplasmic compartments such as stress granules and neuronal RNA granules during cellular stress or during mRNA transport [7]. This dynamic subcellular localization is regulated by post-translational modifications and protein-protein interactions.
One of the primary functions of hnRNP A2/B1 is the regulation of alternative splicing, a critical process that generates protein diversity from a limited number of genes. HnRNP A2/B1 acts as a splicing regulator by binding to specific sequence elements within pre-mRNA transcripts, typically located in intronic regions near splice sites [8]. Through competitive binding with spliceosomal components and other splicing factors, hnRNP A2/B1 influences the inclusion or exclusion of specific exons in the final mRNA transcript.
In neurons, hnRNP A2/B1 regulates the alternative splicing of transcripts encoding proteins critical for neuronal function, including ion channels, neurotransmitter receptors, and components of the synaptic machinery. For example, hnRNP A2/B1 influences the splicing of transcripts involved in axon guidance, synaptic plasticity, and neuronal development [9]. The dysregulation of these splicing events can have profound consequences for neuronal connectivity and function.
In neurons, hnRNP A2/B1 plays a crucial role in the transport of mRNAs from the cell body to distant synaptic compartments. The protein is a component of neuronal RNA granules, which are ribonucleoprotein complexes that facilitate the directed transport of specific mRNAs along cytoskeletal tracks [10]. Through its RNA-binding activity, hnRNP A2/B1 recognizes and binds to localization elements (ZIP codes) within target mRNAs, packaging them into transport granules that are actively transported to dendritic and axonal processes.
This mRNA localization mechanism allows neurons to locally translate proteins at synapses in response to neuronal activity, a process essential for synaptic plasticity, learning, and memory. Target mRNAs for hnRNP A2/B1-mediated transport include transcripts encoding activity-regulated cytoskeletal-associated protein (Arc), calcium/calmodulin-dependent protein kinase II α (CaMKIIα), and microtubule-associated proteins [11]. The localized translation of these proteins at synapses enables rapid responses to neuronal stimulation without requiring new transcription in the nucleus.
HnRNP A2/B1 is a core component of stress granules (SGs), cytoplasmic membraneless organelles that form in response to various cellular stresses, including oxidative stress, heat shock, and viral infection. Stress granules function as triage centers that temporarily store translationally arrested mRNAs and associated proteins, allowing the cell to conserve resources and redirect energy toward stress adaptation [12].
Upon stress induction, hnRNP A2/B1 rapidly translocates from the nucleus to the cytoplasm, where it nucleates the formation of stress granules through liquid-liquid phase separation (LLPS). The low-complexity domain of hnRNP A2/B1 undergoes conformational changes that promote protein-protein interactions and the formation of hydrogel-like structures [13]. These phase-separated compartments concentrate specific sets of mRNAs and proteins while excluding others, allowing for regulated stress responses.
The composition of stress granules includes numerous other RNA-binding proteins, including TIA-1, G3BP1, and TDP-43, creating a dynamic microenvironment that modulates mRNA stability and translation. The reversible nature of stress granule assembly allows for rapid dissolution once the stress is removed, with hnRNP A2/B1 returning to the nucleus.
HnRNP A2/B1 has been implicated in telomere biology, participating in the regulation of telomere length and stability through interactions with telomeric DNA and telomere-binding proteins. The protein can bind to single-stranded telomeric repeats (TTAGGG)n through its RRM domains, similar to its interaction with other GU-rich RNA sequences [14]. This telomeric association suggests a role in protecting chromosome ends from degradation and inappropriate repair.
Beyond its well-characterized roles in post-transcriptional processing, hnRNP A2/B1 can influence gene expression at the transcriptional level. The protein has been shown to interact with transcription factors and chromatin-modifying complexes, potentially regulating the accessibility of specific gene promoters [15]. This transcriptional regulatory function may contribute to the broader impact of hnRNP A2/B1 on cellular homeostasis.
Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disease characterized by the selective death of upper and lower motor neurons, leading to muscle weakness, paralysis, and ultimately respiratory failure. A major breakthrough in understanding ALS pathogenesis came with the identification of dominant mutations in the HNRNPA2B1 gene as causes of familial ALS [16]. These mutations, particularly the P226L and P226H substitutions within the low-complexity domain, are highly penetrant and cause rapid disease progression.
The disease-causing mutations in hnRNP A2/B1 promote the pathological aggregation of the protein within motor neurons. Mutant hnRNP A2/B1 exhibits increased propensity for self-aggregation and forms insoluble cytoplasmic inclusions that are a hallmark of ALS pathology [17]. These aggregates sequester other RNA-binding proteins and mRNAs, disrupting normal RNA processing and transport.
Studies in animal models have demonstrated that expression of mutant hnRNP A2/B1 is sufficient to cause neurodegeneration. In Drosophila models, expression of hnRNP A2/B1 with ALS-associated mutations leads to progressive motor dysfunction and premature death, accompanied by the formation of cytoplasmic aggregates [18]. These findings establish a direct causal relationship between hnRNP A2/B1 dysfunction and neurodegeneration.
The connection between hnRNP A2/B1 and ALS extends beyond direct mutations. The protein interacts with other ALS-linked proteins, including TDP-43 (encoded by TARDBP) and FUS (encoded by FUS), all of which are RNA-binding proteins that form cytoplasmic inclusions in affected neurons [19]. This convergence of multiple RNA-binding proteins into pathological aggregates suggests that disruption of RNA homeostasis is a central mechanism in ALS pathogenesis.
Frontotemporal dementia represents a group of neurodegenerative disorders characterized by progressive atrophy of the frontal and temporal lobes, leading to changes in personality, behavior, and language. Some HNRNPA2B1 mutations that cause ALS are also associated with FTD phenotypes, indicating phenotypic overlap between these conditions [20]. The presence of hnRNP A2/B1 inclusions in FTD brain tissue further supports its role in this disease.
The pathological hallmark of many FTD cases is the accumulation of phosphorylated TDP-43 in cytoplasmic inclusions. Given the functional similarities between hnRNP A2/B1 and TDP-43, it is not surprising that these proteins co-aggregate in disease states [21]. The sequestration of hnRNP A2/B1 within TDP-43 inclusions may contribute to the disruption of RNA processing that characterizes FTD.
Inclusion body myositis (IBM) is an inflammatory myopathy characterized by progressive muscle weakness and the presence of cytoplasmic inclusions in muscle fibers. HnRNP A2/B1 has been implicated in the pathogenesis of IBM, with the protein accumulating in the characteristic inclusion bodies found in affected muscle cells [22]. The involvement of hnRNP A2/B1 in IBM provides another link between hnRNP aggregation and neuromuscular disease.
While the focus on hnRNP A2/B1 has emphasized its role in neurodegeneration, the protein also has important functions in cancer biology. Altered expression of hnRNP A2/B1 has been reported in various malignancies, including lung cancer, breast cancer, and gliomas [23]. The protein's functions in alternative splicing and mRNA localization can be co-opted by cancer cells to promote tumor growth, invasion, and metastasis. High expression of hnRNP A2/B1 is often associated with poor prognosis in cancer patients.
The function of hnRNP A2/B1 is regulated by various post-translational modifications (PTMs) that modulate its subcellular localization, protein-protein interactions, and aggregation propensity:
Phosphorylation of hnRNP A2/B1 by various kinases, including protein kinase C (PKC) and casein kinase 2 (CK2), regulates its nuclear-cytoplasmic shuttling and RNA-binding activity [24]. Phosphorylation within the low-complexity domain can modulate the protein's aggregation properties, with phosphorylation at specific residues promoting or inhibiting phase separation.
Arginine methylation of hnRNP A2/B1 by protein arginine methyltransferases (PRMTs) influences its interactions with other proteins and RNA [25]. Methylation can alter the protein's affinity for specific binding partners and modulate its role in splicing regulation.
Acetylation of lysine residues within hnRNP A2/B1 has been reported and may affect its protein-protein interactions and stability [26]. The acetylation status of hnRNP A2/B1 may be altered in disease conditions, contributing to pathological aggregation.
Sumoylation of hnRNP A2/B1 regulates its activity and may influence its incorporation into stress granules [27]. The balance between sumoylation and desumoylation may be disrupted in neurodegenerative diseases.
HnRNP A2/B1 interacts with numerous proteins to carry out its diverse functions:
The protein forms heteromers with other hnRNP family members, including hnRNP A1, hnRNP A3, and hnRNP C1/C2 [28]. These interactions are important for the assembly of hnRNP complexes that participate in RNA processing.
The interaction between hnRNP A2/B1 and TDP-43 is particularly relevant to ALS and FTD pathogenesis [29]. Both proteins are RNA-binding proteins that can co-aggregate in disease states, and their interaction may influence each other's aggregation propensity.
Similar to TDP-43, FUS is an RNA-binding protein that interacts with hnRNP A2/B1 and is linked to familial ALS [30]. The convergence of multiple RNA-binding proteins in ALS pathology suggests a shared mechanism of disease.
In neurons, hnRNP A2/B1 interacts with motor proteins involved in RNA granule transport, including kinesin heavy chain and dynein light chain [31]. These interactions facilitate the directed transport of mRNAs along microtubules.
The discovery of hnRNP A2/B1 dates back to early studies on heterogeneous nuclear ribonucleoproteins in the 1970s and 1980s, when researchers identified a group of abundant nuclear proteins associated with pre-mRNA processing. Subsequent characterization revealed the existence of multiple related proteins (hnRNP A1, A2/B1, A3, etc.) that together form the hnRNP complex.
The connection between hnRNP A2/B1 and disease was first established through genetic studies of families with inherited ALS. In 2011, researchers identified HNRNPA2B1 as a causative gene for familial ALS and FTD, representing a major advance in understanding the genetic basis of these diseases [32]. This discovery stimulated intense research into the normal functions of hnRNP A2/B1 and the mechanisms by which mutations cause neurodegeneration.
The identification of HNRNPA2B1 mutations as causes of ALS and FTD has important implications for genetic testing and counseling. Individuals with pathogenic HNRNPA2B1 variants can be identified through
Hnrnpa2B1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Hnrnpa2B1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Beyer AL, Christensen ME, Walker BW, LeStourgeon WM. "Identification and characterization of the ubiquitous protein HnRNP A2/B1 as a nuclear matrix protein." Molecular Biology of the Cell. 1997;8(5):913-923.
Mayeda A, Krainer AR. "Regulation of alternative pre-mRNA splicing by hnRNP A1/B1." Molecular and Cellular Biology. 1999;19(7):5227-5238.
Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, Kanagaraj AP, Carter R, Boylan KB, Wojtas AM, Rademakers R, Pinkus JL, Greenberg SA, Trojanowski JQ, Traynor BJ, Smith BN, Topp S, Gkazi AS, Miller J, Shaw CE, Kottlors M, Kirschner J, Lanzau F, Rinaldi C, Chen W, Lomen-Hoerth C, Raitcheva D, Monahan J, Zhang Z, Weihl CC, Kataeva L, Rogaeva E, Zinman L, Poon W, Jirovec D, Gitler AD. "Mutations in prion-like domains in hnRNPA2B1 and HNRNPA1 cause multisystem proteinopathy and ALS." Nature. 2013;495(7442):467-473.
Liu Q, Shu L, Wang J, Liu J, Huang Y, Gu X, Zhang X, Sun L. "HNRNPA2B1 regulates alternative splicing to suppress pancreatic cancer progression." Nature Communications. 2014;5:4628.
Martinez FJ, Pratt GA, Van Nostrand EL, Yeo GW. "The RNA-binding protein repertoire in neuronal development and disease." Neuron. 2016;92(4):757-771.
Deshpande D, Claypool JT, Gade H, Bhardwaj M, Sanka R, Dromard L, Gonzalez L, Bharti K. "hnRNP A2/B1: An emerging target for RNA-based therapeutics and diagnostics." Molecular Therapy - Nucleic Acids. 2021;24:946-964.